AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01808105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Formula
Description: Feeding ad libitum
Study NCT01808105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Formula 1
Description: Feeding ad libitum
Study NCT01808105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Formula 2
Description: Feeding ad libitum
Study NCT01808105 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Human Milk
Description: Feeding ad libitum
Study NCT02510560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTRA-2112
Study NCT02510560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00614068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavioral therapy (TF-CBT)
Description: TF-CBT sessions will include trauma-focused treatment and will teach participants behavioral management and coping skills to overcome their PTSD.
Study NCT00614068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU outpatient sessions will include routine community care and nontrauma-focused therapy.
Study NCT04515238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.
Study NCT04515238 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v.
Study NCT04515238 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 160mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 160mg p.o
Study NCT04515238 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o.
Study NCT02254954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan in combination with RT and TMZ
Description: Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.
Study NCT02001636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resource Instant Protein 88
Description: Protein product: Resource Instant Protein 88, Nestlé Health Nutrition; postoperative intake of 30 - 35 g powder per day over 6 months.
Study NCT02001636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Resource Maltodextrin
Description: Placebo product (Resource Maltodextrin, Nestlé Health Nutrition). Postoperative intake of 30 - 35 g powder per day over 6 months.
Study NCT00495248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group intervention inspired by Lifestyle Redesign
Description: Group intervention inspired by Lifestyle Redesign
Study NCT04071600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuropeptide Y
Description: Intranasal
Study NCT04071600 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intranasal
Study NCT02791100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of chicken eggs
Description: Community is provided with chickens and young children are to receive 2 eggs a day plus egg shell
Study NCT04639596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity, bowling, (SRT).
Description: This study will be a prospective randomized controlled trial (RCT) of Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity (bowling) among Veterans with psychiatric and/or substance use disorders.
Study NCT00495248 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group intervention inspired by Lifestyle Redesign
Description: Group intervention inspired by Lifestyle Redesign
Study NCT00495248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group intervention inspired by Lifestyle redesign
Description: Lifestyle programme once a week for two hours over an intervention period of 9 months
Study NCT02714972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperglycemia Minimization Algorithm
Description: The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
Study NCT00201513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Isolated Transversus abdominis (TrA) exercise
Description: Eight weeks Isolated Transversus abdominis (TrA) exercise(low load) program; Isolated TrA control through biofeedback
Study NCT00201513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sling exercise
Description: Eight weeks sling(high load) exercise program; Isolated TrA control through biofeedback
Study NCT00201513 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group exercise
Description: Eight weeks non-specific group exercise program; Isolated TrA control through biofeedback
Study NCT03277339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Deroxat® (20 mg/day) 3 week; can be increase on week 2 until 50 mg.
Study NCT03277339 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Thermal cure
Description: Thermal cure is realized for 3 weeks
Study NCT02695420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Omecamtiv Mecarbil
Description: oral tablet
Study NCT02695420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 25 mg Omecamtiv Mecarbil
Description: oral tablet
Study NCT02695420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral tablet
Study NCT02695420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 37.5 mg Omecamtiv Mecarbil
Description: oral tablet
Study NCT02695420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg Omecamtiv Mecarbil
Description: oral tablet
Study NCT02773576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone implant
Study NCT00888719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CWP-0403 100mg
Description: 100mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
Study NCT00888719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Tablet not containing CWP-0403 and indistinguishable from CWP-0403 50mg, 100mg tablets.~Twice a day, 1 tablet at a time for 12 weeks
Study NCT00888719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CWP-0403 50mg
Description: 50mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
Study NCT00092443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™, rotavirus vaccine, live, oral, pentavalent
Description: Three doses of RotaTeq™ administered 28 to 70 days apart.
Study NCT00092443 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo matching RotaTeq™
Description: Placebo matching RotaTeq™ administered 28 to 70 days apart.
Study NCT01439828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcystein
Description: Visit 1: Consent signed. Blood and urine analysis. Questionnaires assessing cannabis and tobacco's craving.N-acetylcystein and placebo doses will be increased if craving decreases \<25% compared to previous visit.The doses start at 200 mg x 4/24h to 800 mg x 4/24h.Visit 2 to 5: Medication safety and cannabis craving and withdrawal assessment during 4 weeks.
Study NCT01439828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcystein
Description: Visit 1: Consent signed. Blood and urine analysis. Questionnaires assessing cannabis and tobacco's craving.N-acetylcystein and placebo doses will be increased if craving decreases \<25% compared to previous visit.The doses start at 200 mg x 4/24h to 800 mg x 4/24h.Visit 2 to 5: Medication safety and cannabis craving and withdrawal assessment during 4 weeks.
Study NCT00707941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Children ≤12 years: Suspension by Weight (Kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows:~1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25
Study NCT00707941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children \< 12 years, suspension by weight (kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows 1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25
Study NCT01755819 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Biocomposite interference screw
Study NCT01755819 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Extracortical ACL Tightrope fixation
Study NCT03174600 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The patients were questioned using the Danish Prostatic Symptom Score (DAN-PSS), and evaluated using modified Barthel index, incontinence quality of life questionnaire (I-QOL), and the Mini-Mental Test (MMT) on the 1st, 3rd and 6th months.
Study NCT04775628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior glide humerus in GH joint
Description: Supine inferior glide GH joint
Study NCT04655989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBB-EXA ES Hemodialysis System
Description: The DBB-EXA ES Hemodialysis Delivery System is intended to support an optional online priming, rinseback and emergency bolus features. The appropriate priming of the hollow fiber dialyzer and blood tubing lines removes debris and air prior to device use, as well as ensuring proper rinseback.
Study NCT04655989 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DBB-EXA ES Hemodialysis System
Description: The DBB-EXA ES Hemodialysis Delivery System is intended to support an optional online priming, rinseback and emergency bolus features. The appropriate priming of the hollow fiber dialyzer and blood tubing lines removes debris and air prior to device use, as well as ensuring proper rinseback.
Study NCT03500224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TAK-954
Description: \[14C\]-TAK-954 intravenous infusion.
Study NCT00268853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPOP-R
Description: Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
Study NCT00268853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP-R
Description: Cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
Study NCT00713297 — intervention group
Intervention type: BEHAVIORAL
Intervention: satisfaction questionnaire
Description: Satisfaction questionnaire
Study NCT01885585 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Study NCT01586130 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise in eccentric or concentric mode
Description: In this therapeutic field, isokinetic exercises seem to have a better efficiency than other, more frequently used, kinds of exercises such as isometric or isotonic exercises.
Study NCT01500720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel 25 milligram per square meter (mg/m\^2) intravenously (IV) on Day 1 every 3 weeks (21-day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
Study NCT01500720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan 1.5 mg/m\^2 IV on Day 1 to Day 5 every 3 weeks (21-Day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
Study NCT02633020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 714
Description: Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.
Study NCT02633020 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.
Study NCT03433040 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 17-Hydroxyprogesterone Capronate
Description: 17-Hydroxyprogesterone Capronate 250mg versus 500mg
Study NCT03433040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-Hydroxyprogesterone Capronate
Description: 17-Hydroxyprogesterone Capronate 250mg versus 500mg
Study NCT00249899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and stable statin therapy
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
Study NCT00249899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stable statin therapy
Description: Lapaquistat acetate placebo-matching, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
Study NCT01229293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Articular Surface Replacement (ASR)
Description: Articular surface replacement, DePuy, posterolateral approach used
Study NCT01229293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Total Hip Arthroplasty (THA)
Description: Device: Biomet 28mm
Study NCT00221117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuroprosthesis-FES Therapy
Description: The Compex Motion neuroprostesis, developed by Drs. R. Popovic and Thierry Keller,and company Compex SA, ia a flexible device designed to improve grasping function in both SCI and stroke patients.This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp , and holds a number of advantages over the other existing neuroprostheses.
Study NCT00221117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Ocupational Therapy (COT)
Description: Conventional occupational therapy pertaining to hand function represents control activities against which the FES therapy was assessed. The conventional occupational therapy included: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training.
Study NCT03798353 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.
Description: A matrix-cell construct (PeriCord) will be placed on the ischemic area of the non-candidate revascularization area during a surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.
Study NCT03798353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery by sternotomy
Description: The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed only the by-pass.
Study NCT03241719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Subjects will receive vascularized composite allotransplantation (e.g. facial, hand and/or abdominal wall transplants) under conventional immune suppression. No sooner than 3 months after VCA, subjects will receive a protocol of daily recombinant IL-2 at low doses for 8 weeks.
Study NCT02281383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG)
Study NCT02172690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Staging
Description: Laparoscopic Staging
Study NCT02223494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbogrel
Study NCT01025518 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training
Description: 12 weeks of resistance training in combination with protein and creatine or placebo ingestion
Study NCT01025518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 12 weeks of resistance training in combination with protein and creatine or placebo ingestion
Study NCT01025518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and creatine
Description: 30 g of protein with each training session, 5 g of creatine pr day
Study NCT01025518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrine
Study NCT01119209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Approved by the Danish Medicines Agency
Study NCT01119209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Approved by the Danish Medicines Agency
Study NCT01119209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Approved by the Danish Medicines Agency
Study NCT01169818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous~Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target
Study NCT01169818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous~Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target
Study NCT00515268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256066
Description: GSK256066 will be available as dry powder inhaler with dosing strengths of 12.5, 37.5, 50 micrograms per inhalation.
Study NCT00515268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo inhaler.
Study NCT03822559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL
Description: One drop a time, once daily administration of DE-111A eye drops in the affected eye(s) at 8:00 am (±1h) for 3 months.
Study NCT03822559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL
Description: One drop a time, once daily administration of preservative-free 0.0015% tafluprost eye drops in the affected eye(s) at 8:00 (±1h) for 3 months.
Study NCT02038361 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood draw
Study NCT00806819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib (BIBF1120)
Description: starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
Study NCT00806819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
Study NCT00806819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pemetrexed
Description: 500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
Study NCT00806819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B12
Description: 1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
Study NCT00806819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone (or corticosteroid equivalent)
Description: 4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
Study NCT00806819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
Study NCT00806819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexamethasone (or corticosteroid equivalent)
Description: 4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
Study NCT00806819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B12
Description: 1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
Study NCT00806819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: 400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.